2 Major Reasons to Buy Moderna Stock Before July 31

Moderna faces two significant catalysts before July 31: its Q2 earnings report and an upcoming FDA decision on its seasonal flu vaccine, mRNA-1010. The company has a strong record of beating earnings estimates, and approval of mRNA-1010 would solidify its respiratory franchise. These events could heavily influence the stock's performance despite its significant gains in 2026.